Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission.
H
H
de Lavallade
C
C
Faucher
S
S
Fürst
J
J
El-Cheikh
N
N
Vey
D
D
Coso
R
R
Bouabdallah
A-M
AM
Stoppa
J-A
JA
Gastaut
D
D
Blaise
M
M
Mohty
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000628:therapy; D020350:Graft vs Tumor Effect; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000175:diagnosis / Q000628:therapy*; D015458:Leukemia, T-Cell / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D035781:Siblings; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013997:Time Factors; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D006680:HLA Antigens; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone